Anzeige
Mehr »
Login
Freitag, 18.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Forge bereits +300 %
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QNZN | ISIN: US0977021049 | Ticker-Symbol: 6LP
Tradegate
16.04.25
16:59 Uhr
0,318 Euro
+0,006
+1,76 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BOLT BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
BOLT BIOTHERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3000,32017.04.
0,2990,32617.04.

Aktuelle News zur BOLT BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiBolt Biotherapeutics, Inc. - 8-K, Current Report2
25.03.Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 20254
25.03.Stifel cuts Bolt Biotherapeutics stock price target to $1.252
24.03.Bolt Biotherapeutics GAAP EPS of -$0.42 misses by $0.043
24.03.Bolt Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
24.03.Bolt Biotherapeutics, Inc. - 10-K, Annual Report1
24.03.Bolt Biotherapeutics, Inc. - 8-K, Current Report2
24.03.Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update265BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs),...
► Artikel lesen
BOLT BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
11.02.Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.455-- Targeting Unmet Needs for Treating Solid Tumors-- REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development...
► Artikel lesen
03.01.Bolt Biotherapeutics, Inc. - 8-K, Current Report6
23.12.24Bolt Biotherapeutics, Inc. - 8-K, Current Report1
13.11.24Bolt Biotherapeutics reports Q3 results2
13.11.24Bolt Biotherapeutics GAAP EPS of -$0.40, revenue of $1.14M2
07.11.24Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting135BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001...
► Artikel lesen
13.08.24Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update165Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersAbstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the Society...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1